MFE-296Homo sapiens (Human)Cancer cell line
Also known as: MFE296, MFE 296
Quick Overview
Human cancer cell line for research on cancer biology and drug development.
Detailed Summary
Basic Information
| Database ID | CVCL_1406 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Endometrium[UBERON:UBERON_0001295] |
Donor Information
| Age | 68 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Race | caucasian |
Disease Information
| Disease | Endometrial adenocarcinoma |
|---|---|
| Lineage | Uterus |
| Subtype | Endometrial Carcinoma |
| OncoTree Code | UCEC |
DepMap Information
| Source Type | DSMZ |
|---|---|
| Source ID | ACH-000879_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg306Ter (c.916C>T) | Heterozygous | Germline | PubMed=16418264 |
| MutationSimple | TP53 | p.Tyr220Cys (c.659A>G) | Unspecified | - | PubMed=21173094 |
| MutationSimple | PTEN | p.Thr321fs*23 (c.963delA) | Heterozygous | - | Unknown, Unknown |
| MutationSimple | PTEN | p.Arg130Gln (c.389G>A) | Heterozygous | - | Unknown, Unknown |
| MutationSimple | JAK1 | p.Lys860Asnfs*16 (c.2580delA) | Heterozygous | - | from parent cell line SNU-1 |
| MutationSimple | ERBB3 | p.Cys186fs*20 (c.550delC) | Heterozygous | - | Unknown, Unknown |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Establishment of new epithelial carcinoma cell lines by blocking monolayer formation.
Hackenberg R., Hawighorst T., Hild F., Schulz K.-D.
J. Cancer Res. Clin. Oncol. 123:669-673(1997).